JHL 1188 (trastuzumab biosimilar) / Eden Biologics - LARVOL DELTA

In agreement with Genentech, JHL must destroy its biosimilar cell lines and banks (Center for Biosimilars) - "Genentech has reached a memorandum of understanding with JHL Biotech in its civil lawsuit related to the theft of Genentech’s trade secrets. According to Genentech, the formal settlement, which remains to be executed, requires JHL to stop developing its biosimilars referencing Genentech’s products: rituximab (Rituxan), dornase alfa (Pulmozyme), trastuzumab (Herceptin), and bevacizumab (Avastin). JHL will also be required to destroy all cell lines and cell banks that are associated with these products, and the biosimilar developer must cease using or sharing any of Genentech’s confidential information."

Corporate lawsuit • Discontinuation